Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves in-depth molecular simulations of the ion channel in its native membrane environment, including its open, closed, and inactivated states, along with ensemble virtual screening that focuses on conformational mobility for each state. Tentative binding pockets are identified inside the pore, in the gating area, and at allosteric sites to address every conceivable mechanism of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P22460

UPID:
KCNA5_HUMAN

ALTERNATIVE NAMES:
HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5

ALTERNATIVE UPACC:
P22460; Q4KKT8; Q4VAJ1; Q4VAJ2; Q9UDA4

BACKGROUND:
The protein Potassium voltage-gated channel subfamily A member 5, also known as Kv1.5, plays a pivotal role in the electrical activity of the heart and pancreas by regulating potassium ion flow. This regulation is crucial for processes such as insulin secretion and cardiac rhythm maintenance. Kv1.5's ability to form channels with different properties by partnering with other subunits or isoforms adds to its functional versatility.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Atrial fibrillation, familial, 7, Kv1.5 represents a significant target for drug discovery efforts aimed at treating heart rhythm abnormalities. The protein's role in this common cardiac condition highlights the importance of Kv1.5 modulators in the development of new treatments for atrial fibrillation, offering hope for patients with this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.